Pan Shengzi helps Dafang County, Guizhou to build a "regional early screening comprehensive prevention and control demonstration project of liver cancer"

On July 29, the "regional early screening comprehensive prevention and control demonstration project of liver cancer" in Dafang County, Guizhou Province was officially launched. Entrusted by the Central Committee of the agricultural labor party, guided by the National Cancer Center, the project is jointly implemented by Dafang County Health Bureau, Dafang County People's Hospital and fanshengzi (NASDAQ: GTH), so as to deeply penetrate the cutting-edge technologies, products and services of cancer early screening into the grass-roots market. Following the new exploration of the public health cooperation mode in developed cities represented by Wuxi Huishan, this project is another innovative attempt of Pan Shengzi's cooperation mode in the rural grass-roots medical market. The project will apply the pan born liver cancer early screening liquid biopsy product hccscreentm to carry out early screening, diagnosis and treatment, follow-up and patient management for high-risk groups of liver cancer in Dafang County. Finally, build a comprehensive cancer prevention and control demonstration model integrating screening and diagnosis and treatment with prevention first, prevention and control combined and long-term management. Hccscreentm uses the original research technology of panthenon mutation capsule, which can detect multiple blood samples and multiple different types of biomarkers at the same time without reducing the sensitivity. Combined with this technology, China National Cancer Center launched a large-scale prospective cohort study of liver cancer early screening liquid biopsy in 2019. The research data released recently showed that HCCscreenTM achieved 88% sensitivity and 93% specificity in the prospective cohort of 1615 HBsAg positive patients, and the performance was significantly better than that of ultrasonography combined with AFP detection.